Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...

Alterations in Muscle Tone ll

Alterations in Muscle Tone ll

Alterations in muscle tone are common manifestations of neurological disorders and reflect dysfunction within different nervous system regions. Spasticity, paratonia, and dystonia represent distinct forms of hypertonia, each with unique mechanisms, clinical features, and diagnostic importance.CharacteristicsSpasticity happens from upper motor neuron lesions and is characterized by velocity-dependent resistance to passive movement. Clinical features include:Exaggerated deep tendon reflexesClonus...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Depolarizing Blockers: Pharmocokinetics

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Time to operative care for breast cancer in the Cape Metro West region.

South African journal of surgery. Suid-Afrikaanse tydskrif vir chirurgie·2025

Same author

The alphaherpesvirus gE/gI glycoprotein complex and proteases jointly orchestrate invasion across the host's upper respiratory epithelial barrier.

mBio·2024

Same author

Tunneling Spectroscopy at Megabar Pressures: Determination of the Superconducting Gap in Sulfur.

Physical review letters·2024

Same author

Cdk12 maintains the integrity of adult axons by suppressing actin remodeling.

Cell death discovery·2023

Same author

Benzodiazepine exposures among women of reproductive age in the US, 2004-2018.

Human & experimental toxicology·2021

Same author

Ontogenetic allometry and architectural properties of the paravertebral and hindlimb musculature in Eastern cottontail rabbits (Sylvilagus floridanus): functional implications for developmental changes in locomotor performance.

Journal of anatomy·2019

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Understanding graft-induced dyskinesia.

E L Lane¹, G A Smith

¹Brain Repair Group, School of Bioscience, Cardiff University, Cardiff CF10 3AX, Wales, UK. laneel@cardiff.ac.uk

Regenerative Medicine

|September 28, 2010

Summary

Cell transplantation for Parkinson's disease faces challenges, including abnormal movements post-transplant. This study examines potential causes like graft factors and inflammation to improve Parkinson's disease treatments.

Area of Science:

Neuroscience
Cell Biology
Clinical Neurology

Background:

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons.
Cell transplantation, specifically dopaminergic cells, is a potential therapeutic strategy for PD.
Clinical trials have reported abnormal involuntary movements (dyskinesias) following fetal ventral mesencephalon transplantation in PD patients.

Purpose of the Study:

To evaluate clinical evidence for hypotheses explaining post-transplant dyskinesias in Parkinson's disease.
To assess the role of graft composition, size, L-3,4-dihydroxyphenylalanine (L-DOPA) exposure, and inflammation in transplant-induced dyskinesias.
To review preclinical models used to investigate these hypotheses and inform future therapeutic development.

Main Methods:

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

Related Experiment Videos

Last Updated: Jun 8, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

Systematic review of clinical trial data on dopaminergic cell transplantation for Parkinson's disease.
Analysis of proposed etiological factors for dyskinesia, including graft characteristics and L-DOPA related factors.
Evaluation of preclinical models investigating graft-related complications and inflammatory responses.

Main Results:

Abnormal involuntary movements are a significant complication in dopaminergic cell transplantation for Parkinson's disease.
Multiple factors, including graft properties and L-DOPA exposure, are hypothesized to contribute to these movements.
Preclinical models are crucial for dissecting the mechanisms underlying these adverse effects.

Conclusions:

Further research is needed to elucidate the precise causes of dyskinesias following cell transplantation in Parkinson's disease.
Optimizing graft characteristics and managing L-DOPA exposure are critical for enhancing the safety and efficacy of this therapy.
Improved preclinical models are essential for developing safer and more effective cell-based treatments for Parkinson's disease.